The leading biotechnology company developing alpha particle linked antibodies to treat cancer

Iomab™-B

Iomab-B will begin a pivotal trial for preparing bone marrow of patients with certain blood cancers before they receive a hematopoietic stem cell transplant or HSCT. View Key Opinion Leader Panel Discussion

Actimab-A

Actimab-A Is in a Phase I/II Clinical Trial.  View Key Opinion Leader Panel Discussion

Platform

Technology platform couples monoclonal antibodies with extremely potent but comparatively safe radioactive isotopes, in particular the alpha-emitter Actinium 225